COR Stock Analysis — Cencora
Sector: Healthcare Distribution
AI Verdict
Cencora trades at 14.6x next year's earnings with sky-high growth expectations, so the numbers look cheap for the potential, but the overbought RSI warns of a near-term correction unless the moat-driven growth comes through fast.
Competitive Moat
Cencora operates as a pharmaceutical distribution giant, leveraging scale to negotiate pricing and ensure supply chain reliability for hospitals and pharmacies. Its moat comes from entrenched logistics infrastructure and long-term contracts with major drug manufacturers, making it difficult for new entrants to replicate its network.
Summary
Cencora is flashing an overbought RSI of 77.1 just as analysts project a massive 159.1% jump in earnings over the next year.
Where It Stands
The stock returned just 1.73% over the past year, trades at 14.6x next year's earnings (well below the healthcare sector median of 22x), but its RSI of 77.1 signals overbought territory and risk of a pullback.
Key Metrics
- RSI: 77.1 — Overbought
- Trailing P/E: 37.9x
- Forward P/E: 14.6x
- PEG Ratio: 0.24
- Earnings Growth: +1.6%
- Revenue Growth: +0.1%
- Market Cap: $13.4B
- Dividend Yield: 0.01%
- 1-Year Return: 1.73%
- 52-Week High: $377.54
- 52-Week Low: $244.82
Analyst Consensus
15 Buy · 5 Hold · 0 Sell (20 analysts)
Bull Case
Forward P/E of 14.6x against a forecasted 159.1% EPS surge means you're paying a low price for explosive earnings growth if it materializes.
Bear Case
With an RSI of 77.1, a typical pullback to neutral (RSI 50–65) could mean a sharp short-term drop even if the forward P/E looks attractive.
Catalyst to Watch
Watch for next quarter's earnings release—if the company delivers on the 159.1% EPS growth, the low forward P/E could quickly look like a bargain.